Opportunity to undertake an MSc in Health Economics at the University of London

By HEOR Staff Writer

February 10, 2023

Opportunity to undertake an MSc in Health Economics at the University of London. Apply for a Fellowship Programme by 30 April 2023.

The Office of Health Economics (OHE) provides various forms of support to the upcoming generation of health economists in order to fulfil our philanthropic goals. They have established an MSc Fellowship Programme in collaboration with City, University of London, and a PhD Programme at LSE, London School of Economics and Political Science, for individuals interested in pursuing postgraduate studies in health economics.

Their objective is to ensure the continued role of health economics in high-quality, evidence-based health policy decision-making and to strengthen and advance the discipline’s future.

For further information, please visit:

Reference url

Recent Posts

Advancing the Biosimilar Approval Framework: A Shift Towards Analytical Comparability

By HEOR Staff Writer

April 6, 2026

Below we highlight how the European Medicines Agency (EMA) is reshaping the biosimilar approval framework by prioritising advanced analytical characterisation over traditional comparative efficacy studies. A recently finalized reflection paper outlines a science-based, tailored clinical develo...
Current Challenges in Outcome Transparency Healthcare in Dutch Medical Specialist Care

By João L. Carapinha

In this update we highlight the persistent shortcomings in outcome transparency in Netherland's healthcare system. The 2026 baseline measurement report published by Zorginstituut Nederland and Patiëntenfederatie Nederland shows that national ambitions for transparency of care outcomes in medical ...
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role in Treating PD-L1-P...

By HEOR Staff Writer

Immunotherapy ovarian cancer treatment has taken a major step forward in Europe. The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary...